logo-loader
viewZynerba Pharmaceuticals

SCYNEXIS names Zynerba CEO Armando Anido to its board

Anido boasts more than 30 years of experience in the biopharmaceutical sector

empty board room
Prior to his tenure at Zynerba, Anido served as CEO of NuPathe Inc

SCYNEXIS Inc (NASDAQ:SCYX) announced Tuesday that it has tapped Armando Anido to its board of directors.

Anido is currently the chairman and CEO of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a job he has held since October of 2014.

“On behalf of my fellow board members, I would like to welcome Armando and look forward to his contributions as we carry out the important work of bringing novel antifungal treatments to patients,” said Guy Macdonald, chairman of the board of the New Jersey-based biotech, in a statement.

READ: Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products

Anido boasts more than 30 years of experience in the biopharmaceutical sector. Prior to his tenure at Zynerba, Anido served as CEO of NuPathe Inc, which was acquired by Teva Pharmaceuticals in February of 2014. He also previously was at the helm as CEO at Auxilium  Pharmaceuticals, which was acquired by Endo Pharmaceuticals in January of 2015.

SCYNEXIS’s lead drug candidate is ibrexafungerp (formerly known as SCY-078), an antifungal agent in clinical development for the treatment of serious and life-threatening fungal infections caused by candida and aspergillus species.

SCYNEXIS shares popped by 3.7% to $0.77 in Tuesday’s morning trading session.

Contact Ellen Kelleher at [email protected]

Quick facts: Zynerba Pharmaceuticals

Price: 6.53 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $151.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read